311 related articles for article (PubMed ID: 22076958)
1. CD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markers.
Chen J; Guo T; Zhang L; Qin LX; Singer S; Maki RG; Taguchi T; Dematteo R; Besmer P; Antonescu CR
Genes Chromosomes Cancer; 2012 Feb; 51(2):186-95. PubMed ID: 22076958
[TBL] [Abstract][Full Text] [Related]
2. Highly enriched CD133(+)CD44(+) stem-like cells with CD133(+)CD44(high) metastatic subset in HCT116 colon cancer cells.
Chen KL; Pan F; Jiang H; Chen JF; Pei L; Xie FW; Liang HJ
Clin Exp Metastasis; 2011 Dec; 28(8):751-63. PubMed ID: 21750907
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of CD44 and CD133 as cancer stem cell markers for colorectal cancer.
Wang C; Xie J; Guo J; Manning HC; Gore JC; Guo N
Oncol Rep; 2012 Oct; 28(4):1301-8. PubMed ID: 22895640
[TBL] [Abstract][Full Text] [Related]
4. High CD133 expression levels in gastrointestinal stromal tumors.
Bozzi F; Conca E; Manenti G; Negri T; Brich S; Gronchi A; Pierotti MA; Tamborini E; Pilotti S
Cytometry B Clin Cytom; 2011; 80(4):238-47. PubMed ID: 21462307
[TBL] [Abstract][Full Text] [Related]
5. Cancer stem-like cells in human prostate carcinoma cells DU145: the seeds of the cell line?
Wei C; Guomin W; Yujun L; Ruizhe Q
Cancer Biol Ther; 2007 May; 6(5):763-8. PubMed ID: 17592251
[TBL] [Abstract][Full Text] [Related]
6. Non-small cell lung cancer cells expressing CD44 are enriched for stem cell-like properties.
Leung EL; Fiscus RR; Tung JW; Tin VP; Cheng LC; Sihoe AD; Fink LM; Ma Y; Wong MP
PLoS One; 2010 Nov; 5(11):e14062. PubMed ID: 21124918
[TBL] [Abstract][Full Text] [Related]
7. Cells with characteristics of cancer stem/progenitor cells express the CD133 antigen in human endometrial tumors.
Rutella S; Bonanno G; Procoli A; Mariotti A; Corallo M; Prisco MG; Eramo A; Napoletano C; Gallo D; Perillo A; Nuti M; Pierelli L; Testa U; Scambia G; Ferrandina G
Clin Cancer Res; 2009 Jul; 15(13):4299-311. PubMed ID: 19509143
[TBL] [Abstract][Full Text] [Related]
8. Aberrant expression of cancer stem cell markers (CD44, CD90, and CD133) contributes to disease progression and reduced survival in hepatoblastoma patients: 4-year survival data.
Bahnassy AA; Fawzy M; El-Wakil M; Zekri AR; Abdel-Sayed A; Sheta M
Transl Res; 2015 Mar; 165(3):396-406. PubMed ID: 25168019
[TBL] [Abstract][Full Text] [Related]
9. The study of the tumor stem cell properties of CD133+CD44+ cells in the human lung adenocarcinoma cell line A549.
Zhang HZ; Lin XG; Hua P; Wang M; Ao X; Xiong LH; Wu C; Guo JJ
Cell Mol Biol (Noisy-le-grand); 2010 Sep; 56 Suppl():OL1350-8. PubMed ID: 20937222
[TBL] [Abstract][Full Text] [Related]
10. Side population rather than CD133(+) cells distinguishes enriched tumorigenicity in hTERT-immortalized primary prostate cancer cells.
Zhou J; Wang H; Cannon V; Wolcott KM; Song H; Yates C
Mol Cancer; 2011 Sep; 10():112. PubMed ID: 21917149
[TBL] [Abstract][Full Text] [Related]
11. Cancer stem cell markers are enriched in normal tissue adjacent to triple negative breast cancer and inversely correlated with DNA repair deficiency.
Atkinson RL; Yang WT; Rosen DG; Landis MD; Wong H; Lewis MT; Creighton CJ; Sexton KR; Hilsenbeck SG; Sahin AA; Brewster AM; Woodward WA; Chang JC
Breast Cancer Res; 2013; 15(5):R77. PubMed ID: 24008095
[TBL] [Abstract][Full Text] [Related]
12. Kitlow stem cells cause resistance to Kit/platelet-derived growth factor alpha inhibitors in murine gastrointestinal stromal tumors.
Bardsley MR; Horváth VJ; Asuzu DT; Lorincz A; Redelman D; Hayashi Y; Popko LN; Young DL; Lomberk GA; Urrutia RA; Farrugia G; Rubin BP; Ordog T
Gastroenterology; 2010 Sep; 139(3):942-52. PubMed ID: 20621681
[TBL] [Abstract][Full Text] [Related]
13. Prolonged drug selection of breast cancer cells and enrichment of cancer stem cell characteristics.
Calcagno AM; Salcido CD; Gillet JP; Wu CP; Fostel JM; Mumau MD; Gottesman MM; Varticovski L; Ambudkar SV
J Natl Cancer Inst; 2010 Nov; 102(21):1637-52. PubMed ID: 20935265
[TBL] [Abstract][Full Text] [Related]
14. Coexpression of CD44-positive/CD133-positive cancer stem cells and CD204-positive tumor-associated macrophages is a predictor of survival in pancreatic ductal adenocarcinoma.
Hou YC; Chao YJ; Tung HL; Wang HC; Shan YS
Cancer; 2014 Sep; 120(17):2766-77. PubMed ID: 24839953
[TBL] [Abstract][Full Text] [Related]
15. Expression of cancer stem cell markers ALDH1, CD44 and CD133 in primary tumor and lymph node metastasis of gastric cancer.
Wakamatsu Y; Sakamoto N; Oo HZ; Naito Y; Uraoka N; Anami K; Sentani K; Oue N; Yasui W
Pathol Int; 2012 Feb; 62(2):112-9. PubMed ID: 22243781
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of cancer stem cell markers CD133, CD44, CD24: association with AKT isoforms and radiation resistance in colon cancer cells.
Sahlberg SH; Spiegelberg D; Glimelius B; Stenerlöw B; Nestor M
PLoS One; 2014; 9(4):e94621. PubMed ID: 24760019
[TBL] [Abstract][Full Text] [Related]
17. Expression profiling of GIST: CD133 is associated with KIT exon 11 mutations, gastric location and poor prognosis.
Arne G; Kristiansson E; Nerman O; Kindblom LG; Ahlman H; Nilsson B; Nilsson O
Int J Cancer; 2011 Sep; 129(5):1149-61. PubMed ID: 21064103
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical detection of cancer stem cell related markers CD44 and CD133 in metastatic colorectal cancer patients.
Pitule P; Cedikova M; Daum O; Vojtisek J; Vycital O; Hosek P; Treska V; Hes O; Kralickova M; Liska V
Biomed Res Int; 2014; 2014():432139. PubMed ID: 24864242
[TBL] [Abstract][Full Text] [Related]
19. Colon cancer stem cell markers CD44 and CD133 in patients with colorectal cancer and synchronous hepatic metastases.
Jing F; Kim HJ; Kim CH; Kim YJ; Lee JH; Kim HR
Int J Oncol; 2015 Apr; 46(4):1582-8. PubMed ID: 25625240
[TBL] [Abstract][Full Text] [Related]
20. Enrichment of prostate cancer stem-like cells from human prostate cancer cell lines by culture in serum-free medium and chemoradiotherapy.
Wang L; Huang X; Zheng X; Wang X; Li S; Zhang L; Yang Z; Xia Z
Int J Biol Sci; 2013; 9(5):472-9. PubMed ID: 23781140
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
